ReviewInternational journal of molecular sciences2025
Potential Biomarker and Therapeutic Tools for Pathological Cardiac Hypertrophy and Heart Failure: Extracellular Vesicles.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Immunologically Adaptive Endovascular Devices: Integrating Thrombo-Inflammation, Biomaterials Design, and Artificial Intelligence for Precision Cardiovascular Intervention.International journal of molecular sciences · 2026Review
- MicroRNAs in Heart Failure Pathogenesis and Progression: Mechanistic Control, Biomarker Potential, and Translational Perspectives.Life (Basel, Switzerland) · 2026Review
- From polygenic risk to digital twins: the future of personalised cardiovascular medicine.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cardiovascular disease remains the leading global cause of death. Pathological cardiac hypertrophy is a key precursor to heart failure (HF), a condition with high morbidity and mortality. Extracellular vesicles (EVs) have emerged as crucial mediators of intercellular communication, carrying bioactive cargoes that reflect cellular state and influence recipient cell function. This review provides a focused and integrative perspective distinct from broader overviews, by dissecting the dynamic, cell-type-specific roles of EVs across the continuum from pathological hypertrophy to overt HF. We critically synthesize evidence on how EVs derived from cardiomyocytes, fibroblasts, immune cells, and adipocytes orchestrate maladaptive remodeling. Furthermore, we evaluate their dual utility as emerging diagnostic biomarkers and as engineerable therapeutic vectors. By highlighting recent advances in EV engineering for targeted delivery and discussing persistent translational challenges, this article offers a unique mechanistic-to-translational viewpoint aimed at advancing the therapeutic application of EVs in cardiovascular medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.